Courtagen Submits Pre-IDE to FDA for C-reactive Protein Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said it has submitted its first pre-investigational device exemption information package to US regulators for its automated solution for measuring C-reactive proteins in a clinical setting.

In addition to its submission to the US Food and Drug Administration, Courtagen is pursuing a CE Mark for the solution, which is comprised of its Avantra Q400 BioMarker Workstation and the QPDx BioChip.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.